Amphastar’s Price Target Cut to $20 on Limited Growth Catalysts
AMPH•Bank of America lowered Amphastar Pharmaceuticals’ rating to Underperform and cut its price objective from $25 to $20, citing limited near-term growth catalysts and constrained legacy generics revenue. Analysts warned the transition to proprietary brands and biosimilars could delay meaningful upside for the company.
1. Bank of America Downgrades Amphastar
Bank of America has lowered Amphastar Pharmaceuticals’ rating to Underperform and trimmed its price objective to $20 from $25, reflecting concerns about the stock’s risk-reward following recent performance. The adjustment marks a 20% reduction in the target and signals diminished near-term upside.
2. Limited Near-Term Growth Catalysts
Analysts highlighted the absence of imminent product launches or clinical data, emphasizing that Amphastar’s pipeline lacks significant catalysts before late-stage readouts. The company’s reliance on legacy generic products, which are facing pricing pressures and competitive headwinds, further dampens short-term growth prospects.
3. Transition to Proprietary Brands and Biosimilars
Amphastar is in the midst of shifting from a generic manufacturer to a proprietary brands and biosimilars model, a process expected to span multiple years. This strategic pivot, while essential for long-term value creation, may delay meaningful revenue upside as new product development and commercialization capabilities are built.
